Maisoun Sulfab

Maisoun Sulfab is a patent agent with the firm with a biotechnology background. She earned a Bachelors of Science in molecular and cellular biology from Marymount University in Arlington VA in 1998. She earned a Masters of Science degree in molecular and cellular biology from California State University at Sacramento in 2006. She earned a Juris Doctor degree from San Francisco School of Law in 2013 while working full-time in discovery research for a pharmaceutical company.

Ms. Sulfab focuses her practice on patent preparation and prosecution in the areas of biotechnology, pharmaceuticals, and medical devices. Her work includes technologies such as antibodies, molecular biology techniques, vaccines, gene therapy, protein, and cellular biology. Ms. Sulfab has experience in performing patentability, validity, and freedom to operate searches. The depth of her technical background and her experience in patent prosecution enable her to work efficiently with inventors and the U.S Patent and Trademark Office. Furthermore, she has been involved in evaluation of biotechnologies for a capital investment firm. Ms. Sulfab has worked with start-up companies to help develop their intellectual property portfolios as well. She has performed due diligence for clients during their venture financing stage. Prior to entering the legal profession, Ms. Sulfab worked for more than a decade in biotechnology and pharmaceutical companies. She also held positions in discovery research working in oncology, fibrosis, and virology. During her research career, Ms. Sulfab was published in top-tier scientific journals and attracted publicity in the scientific community. Ms. Sulfab is a member of the IP Inn Court of California.

BAR ADMISSIONS

  • California (pending)
  • U.S. Patent & Trademark Office

PUBLICATIONS/PRESENTATIONS

Zhang, Y., Sulfab, M., & Fernandez, D., “Intellectual Property Protection Strategies for Nanotechnology,” Nanotechnology Reviews (2013).

Hebner, C.M., Han, B., Brendza, K.M., Nash, M., Sulfab, M., et al., “The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function,” PLoS One 7(6):e39163 (2012).

Brendza, K.M., Lichti, C., Vivian R., Hebner, C.M., Petra, G., Sulfab, M., Tayler, J., et al., “Mass Spectrometry as a Tool to Uncover a Novel Mechanism of Action for the HCV NS5B Polymerase Non-nucleoside Inhibitor Tegobuvir,” J Am Soc Mass Spectrom (2012).

Sulfab, M., Blat, L.M., Ozes, O., “Pirfenidone and Induced Epithelial to Mesenchymal Transition Interferon-Gamma 1b Inhibit TGFβ in Alveolar Epithelial Cells and Differentiation of Human Lung Fibroblasts,” Am J Respir Crit Care Med; 175: A729 (2007).

Sulfab, M., Blat, L.M., Ozes, O, “The Effects of Pirfenidone and Interferon Inducible T- Cell Alpha Chemoattractant on Transforming Growth Factor-β1-Mediated Synthesis of Extracellular Matrix Proteins in Endothelial Cells,” Am J Respir Crit Care Med ; 175: A730 (2007).

Sulfab, M., Singh, B., Landerholm, T.E., “The Control of Coronary Artery Smooth Muscle Differentiation by Exogenous Growth Factors In Vitro and Elimination of Transforming Growth Factor-β Receptor Type II by Dominant-Negative Inhibition,” Mol Biol Cell 22:L367 (2005).